Precursor Condition
Monoclonal Gammopathy of Undetermined Significance
CI-CAN-00006048MGUSExplore in graph →
HematologicPrecursor13 active trials
Loading cancer entity…
Loading cancer entity…
Precursor Condition
CI-CAN-00006048MGUSExplore in graph →
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01139476 | Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study | completed | — | 1,892 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT01237054 | Imaging in MGUS, SMM and MM | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05565638 | PROFAST Intervention in Precursor Multiple Myeloma(PROFAST) | completed | N/A | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT03951220 | The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss(LOOMIS) | completed | — | 67 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04615572 | Screening to Improve Survival in AL Amyloidosis | completed | — | 35 | Tufts Medical CenterOTHER | 1 | Oct 28, 2024 | clinicaltrials |
| NCT03119883 | Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma | completed | N/A | 35 | Mayo ClinicOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04439006 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | completed | Phase 1 | 10 | Jennifer WoyachOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02566265 | Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients(SHIVERING 2) | completed | Phase 2 | 122 | Yale UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01955395 | Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma | completed | N/A | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT00099047 | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT00900263 | S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma | completed | — | 375 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 7, 2016 | clinicaltrials |
| NCT00919139 | S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | completed | — | 190 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 3, 2015 | clinicaltrials |
| NCT01219010 | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | completed | Phase 1 | 30 | Janssen Research & Development, LLCINDUSTRY | 3 | Jan 19, 2015 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2026source: clinicaltrials